CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D020182: Sleep Apnea, Central NIH

(Synonyms: Sleep Apnea, Central)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug415 Buspirone + PAP therapy Wiki 1.00
drug2722 Zolpidem + PAP therapy Wiki 1.00
drug114 Acetazolamide + supplemental oxygen + PAP therapy Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D012891 Sleep Apnea, NIH 0.50
D053120 Respiratory Aspiration NIH 0.38

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002871 Central apnea HPO 1.00
HP:0010535 Sleep apnea HPO 0.50

There is one clinical trial.

Clinical Trials


1 Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

NCT04118387 Sleep Disordered Breathing Able Bodied Drug: Acetazolamide + supplemental oxygen + PAP therapy Drug: Zolpidem + PAP therapy Drug: Buspirone + PAP therapy
MeSH:Sleep Apnea Syndromes Respiratory Aspiration Sleep Apnea, Central
HPO:Central apnea Central sleep apnea Sleep apnea

Primary Outcomes

Description: CO2 reserve is the requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative.

Measure: CO2 reserve

Time: 120 days

Description: Central apnea indices is used to indicate the severity of central sleep apnea

Measure: Central apnea indices

Time: 120 days

Secondary Outcomes

Description: Controller gain is a ventilatory response to changes in end-tidal PCO2

Measure: Controller gain

Time: 120 days

Description: Plant gain is blood gas response to a change in ventilation. This measure represents the effectiveness of the "plant" in eliminating CO2.

Measure: Plant gain

Time: 120 days

Description: This measure represents the activity of the carotid bodies. It is measured by the decrease in ventilation in response to a single breath of 100% oxygen.

Measure: Carotid body function

Time: 120 days

Description: Peripheral chemoreflex sensitivity is measured either via brief hypoxia or a single breath of CO2.

Measure: Peripheral chemoreflex sensitivity

Time: 120 days

Description: The nadir pressure in the upper airway (supra-glottic pressure) prior to the occurrence of an arousal.

Measure: Respiratory arousal threshold

Time: 120 days

Description: To assess breathing stability, the investigators will measure % stable breathing using minute ventilation (VE) and tidal volume (VT) coefficient of variation as indices of breathing instability.

Measure: % stable breathing

Time: 120 days


HPO Nodes